Kiran Mazumdar-Shaw

Founder at Biocon Ltd.

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw

Founder at Biocon Ltd.

Overview
Career Highlights

Biocon Ltd.
Biocon Foundation

RelSci Relationships

1218

Number of Boards

36

Birthday

03/23/1953

Age

65

Number of Awards

26

Estimated Net Worth

$2.1B

Relationships
RelSci Relationships are individuals Kiran Mazumdar-Shaw likely has professional access to. A relationship does not necessarily indicate a personal connection.

Vice Chairman at Biocon Ltd.

Relationship likelihood: Strong

Chief Executive Officer, Executive Director & Managing Director at Biocon Ltd.

Relationship likelihood: Strong

Member-Finance Commission at International Federation of Red Cross and Red Crescent Societies

Relationship likelihood: Strong

Representative Executive Officer, President & Chief Executive Officer at Sosei Group Corp.

Relationship likelihood: Strong

Founder & Chairman at Narayana Hrudayalaya Ltd.

Relationship likelihood: Strong

Professor at Purdue University

Relationship likelihood: Strong

Executive Chairman at Biolinq, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Syngene International Ltd.

Relationship likelihood: Strong

Chief Operating Officer & Director at Infosys Ltd.

Relationship likelihood: Strong

Member, Board of Directors at Biocon Ltd.

Relationship likelihood: Strong

Paths to Kiran Mazumdar-Shaw
Potential Connections via
Relationship Science
You
Kiran Mazumdar-Shaw
Founder at Biocon Ltd.
Family Members
Family Member
Professor at Purdue University

Purdue University, located in West Lafayette, Indiana, is the flagship university of the six-campus Purdue University system. Purdue was founded on May 6, 1869, as a land-grant university when the Indiana General Assembly, taking advantage of the Morrill Act, accepted a donation of land and money from Lafayette businessman John Purdue to establish a college of science, technology, and agriculture in his name. The first classes were held on September 16, 1874, with six instructors and 39 students. The university was founded with the gift of $150,000 from John Purdue, a Lafayette business leader and philanthropist, along with $50,000 from Tippecanoe County, and 150 acres (0.6 km²) of land from Lafayette residents in support of the project. In 1869, it was decided that the new school would be built near the city of Lafayette and established as Purdue University, in the name of the institution’s principal benefactor. The West Lafayette campus offers more than 200 majors for undergraduates, over 70 master’s and doctoral programs, and professional degrees in pharmacy and veterinary medicine. In addition, Purdue has 18 intercollegiate sports teams and more than 850 student organizations. Today, Purdue is a member of the Big Ten Conference. Purdue enrolls the second largest student body of any university in Indiana as well as the fourth largest international student population of any university in the United States.

Spouse
Vice Chairman at Biocon Ltd.

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Education
Master Brewer
Class of 1975

University of Ballarat is a management consulting firm serving the public and higher education sectors.

Bachelor's Degree in Zoology
Class of 1973

Bangalore University is a public college level educational facility located in Bangalore.

Attendee
Class of 1968
Memberships
Member
Current

The Giving Pledge is a campaign to encourage the wealthiest people in the world to make a commitment to give most of their wealth to philanthropic causes. The campaign specifically focuses on billionaires and was made public in 2010 by Warren Buffett and Bill Gates. The Huffington Post reported in April 2012 that "81 billionaires committed to giving at least half of their fortunes to charity". As of July 2013, 113 billionaire individuals and couples and one family group have signed the pledge.

Career History
Managing Director
1993 - Current

Syngene International Ltd. operates as a contract research organization, which provides discovery and development services for novel molecular entities. The company's services include discovery chemistry, discovery biology, safety assessment, large molecule development, chemical development, formulation development stability, polymer research, integrated discover & development and clinical development services. Its development platforms serve industries such as pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition sectors. The company was founded on November 18, 1993 and is headquartered in Bangalore, India.

Founder
1978 - Current

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Founder
Current
Boards & Committees
Director
2018 - Current

The U.S.-India Business Council is the premier business advocacy organization representing America's top companies investing in India, joined by global Indian companies, with an aim to deepen trade and strengthen commercial ties. The U.S.-India Business Council is the principal interlocutor for industry operating in the U.S. and Indian marketplace, playing a critical role supporting U.S. Government initiatives that include the U.S.-India Economic Dialogue (CEO Forum), the U.S.-India High Technology Cooperation Group, U.S.-India Energy Dialogue, the Defense Procurement & Production Group, and the U.S.-India Trade Policy Forum. USIBC formulates an annual work plan that targets specific issues important to its member-companies, compiled from input derived from the 12 Executive Committees and Working Groups that meet regularly to assess progress on-the-ground and to devise strategies and prepare representations to advance sector-specific reforms in India. In addition, USIBC's Executive Committees organize industry missions to India to present to counterparts and the Government of India a united front to forge policy reform advances.

Lead Independent Director
2013 - Current

What We Do Infosys Limited (NYSE: INFY) was started in 1981 by seven people with US$ 250. Today, we are a global leader in consulting, technology and outsourcing with revenues of US$ 7.231 billion (LTM Q3 FY13). Many of the world’s most successful organizations rely on Infosys to deliver measurable business value. Infosys provides business consulting, technology, engineering and outsourcing services to help clients in over 30 countries build tomorrow’s enterprise. Our award-winning Infosys Labs and its breakthrough intellectual property can be leveraged as a co-creation engine to accelerate innovation across the enterprise. Infosys pioneered the Global Delivery Model (GDM), based on the principle of taking work to the location where the best talent is available, where it makes the best economic sense, with the least amount of acceptable risk. Continued leadership around GDM enables Infosys to drive extraordinary efficiencies and free up clients’ resources for strategic transformation or innovation initiatives. Infosys has a global footprint with 67 offices and 69 development centers in US, India, China, Australia, Japan, Middle East, UK, Germany, France, Switzerland, Netherlands, Poland, Canada and many other countries. Infosys and its subsidiaries have 155,629 employees as on Dec 31, 2012. Infosys takes pride in building strategic long-term client relationships. 97.5% of our revenues come from existing customers (Q3 FY 13). Infosys gives back to the community through the Infosys Foundation that funds learning and educatio

Independent Non-Executive Director
2009 - Current

UBL has an association with brewing dating back over nine decades, starting with 5 breweries in South India in 1915. From bullock cart-loaded barrels or 'hogheads' of frothing ale, the beer business has gone on to become the undisputed 'king' in the Indian beer market. UBL today boasts an impressive spread of own and contract manufacturing facilities throughout the country. Here, innovative, creative and aggressive marketing is complemented by a strong distribution network. A management focused on building brand equity on one hand and exploiting it to the hilt on the other. Quality and hygiene are the key elements of the United Breweries' manufacturing philosophy. To this end, the Central Scientific Laboratory (CSL), headquartered at Bangalore sets standards for all its breweries. Quality Management Systems laid out along the lines of ISO 9000 are strictly adhered to, controlling quality at every stage of production, from raw materials to the end product. Also, besides controlling the production process, the CSL analyses the Company's beer taken off market shelves all over the country, the competition's beers and beers from across the world. These beers are tested as per the standards laid down by the European Brewery Convention on 40 different parameters. By these standards, United Breweries' beers don't just equal, but even surpass, several Dutch and American beers. Its flagship brand 'Kingfisher', has achieved international recognition consistently, and has won many awards in International Beer Festivals. Kingfisher Premium Lager beer is currently available in 52 countries and leads the way amongst Indian beers in the International market. It has been ranked amongst the top 10 fastest growing brands in the UK

Member, Board of Trustees
2018 - Current

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Member, Board of Directors
2016 - Current

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Member, Board of Trustees
Current

KGI is dedicated to education and research aimed at translating life sciences into practice.

Director
Tenure Unconfirmed
Director
Tenure Unconfirmed
Investments
Details Hidden

Narayana Hrudayalaya Ltd. engages in the provision of health care services. It provides services in the areas of cardiac surgery, cardiology, diabetes and endocrinology, gastroenterology, general surgery, neurosciences, facial surgery, nephrology, obstetrics and gynecology, orthopedics, oncology, pediatrics, transplant, urology, and vascular surgery; and other specialty services, such as dental, dermatology, emergency medicine, ears, nose, and throat, family medicine, general medicine, and genetic. The company was founded by Devi Prasad Shetty on July 19, 2000 and is headquartered in Bangalore, India.

Details Hidden

XCyton Diagnostics Pvt Ltd. operates as a molecular biology company which provides diagnostic products. It offers syndrome evaluation system which allows the simultaneous identification of multiple organisms inclusive of bacteria, viruses, fungi and parasites, in a specific test from a single sample. The firm also develops immunodiagnostic kits for the detection of infections. The company was founded by Venkata Ravi Kumar Banda on September 30, 1993 and is headquartered in Bangalore, India.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #973
2017
Forbes Magazine - The World's Billionaires
Rank #71
2016
Hurun – The Richest People in India
Rank #1741
2015
Forbes Magazine - The World's Billionaires
Events
Speaker
Singapore, CE, Singapore
2013 Wall Street Journal Unleashing Innovation Conference

Attendee
Gurgaon, CT, India
2012 World Economic Forum on India

From Deliberation to Transformation

Attendee
Ambience Island National Highway 8-Gurgaon , Haryana
2012 World Economic Forum on India

From Deliberation to Transformation